Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T2DM (Type 2 Diabetes Mellitus): early-phase trial registry
3 of 5 indexed T2DM (Type 2 Diabetes Mellitus) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
T2DM (Type 2 Diabetes Mellitus): 5 US clinical trials tracked, 3 recruiting.
T2DM (Type 2 Diabetes Mellitus) is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Ascletis Pharma (China) Co., Limited, running 1 of these trials.
Enrollment posture brief
Registry condition t2dm-type-2-diabetes-mellitus
OPEN 3 | RECR 60% | LATE 0 | EARLY 2 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
T2DM (Type 2 Diabetes Mellitus) lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for T2DM (Type 2 Diabetes Mellitus) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
T2DM (Type 2 Diabetes Mellitus) is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates T2DM (Type 2 Diabetes Mellitus) research.
Ascletis Pharma (China) Co., Limited accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most T2DM (Type 2 Diabetes Mellitus) trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
T2DM (Type 2 Diabetes Mellitus) splits between interventional and observational designs.
3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Ascletis Pharma (China) Co., Limited
NCT07321678
Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
University of North Carolina, Chapel Hill
NCT07148713
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D
University of Colorado, Denver
NCT07005362
Virtual Diabetes Group Visits Across Health Systems
University of Chicago
NCT06094491
Nutritional Therapy for Diabetic Cardiomyopathy
Washington University School of Medicine
NCT01373814
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on T2DM (Type 2 Diabetes Mellitus) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on T2DM (Type 2 Diabetes Mellitus) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this T2DM (Type 2 Diabetes Mellitus) page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 T2DM (Type 2 Diabetes Mellitus) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ascletis Pharma (China) Co., Limited sponsors the most T2DM (Type 2 Diabetes Mellitus) trials on record, review their full trial history before evaluating a specific study. See Ascletis Pharma (China) Co., Limited's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This T2DM (Type 2 Diabetes Mellitus) condition card totals 5 registered trials; most-linked intervention Virtual Group Visit; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.